In February of 2024, the US Food & Drug Administration approved Lifileucel (Amtagvi, Iovance Biotherapeutics, Inc., San Carlos, CA, USA ), a novel TIL-based therapy to treat unresectable or metastatic melanoma in patients who had previously received a PD-1 blocking antibody or BRAF inhibitor (with or without a MEK inhibitor if BRAF V600+) [96]. The gene discussed is BRAF; the disease is metastatic melanoma.